Aerie Pharmaceuticals, Inc.
Aerie is an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for open-angle glaucoma, ocular surface diseases and retinal diseases. In the U.S., Aerie markets Rhopressa® (netarsudil ophthalmic solution) 0.02%, a Rho kinase (ROCK) inhibitor, and Rocklatan® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005%. Rhokiinsa® (netarsudil ophthalmic solution) 0.02% and Roclanda® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% are approved in the EU and UK. Following a Phase 3 trial of netarsudil in collaboration with Santen, the Japanese-based company will oversee the rest of development in Japan. The pipeline also includes two Phase 3-ready products with AR-15512 (TRPM8 agonist) for dry eye, and AR-1105 (dexamethasone) Sustained Release Implant for retinal disease. For more information, please visit www.aeriepharma.com.
Additional Lines: Rocklatan®, Rhopressa®
Legend
Available Timeslot
Scheduled Appointment
Personal Appointments
Appointment Request
Blocked Timeslot
Restricted Timeslot